NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
Clinical Trials
24 trialsNCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT00412022 2023-03-24
HOBOE
National Cancer Institute, Naples
Phase 3 Unknown
NCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT05164952 2021-12-21
Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
Assiut University
Phase 3 Unknown
NCT00127205 2021-07-02
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
SWOG Cancer Research Network
Phase 3 Completed
NCT01099436 2020-01-21
NEO-ZOTAC
Borstkanker Onderzoek Groep
Phase 3 Completed
NCT00130494 2019-04-16
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Spanish Breast Cancer Research Group
Phase 3 Terminated
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00107263 2016-12-06
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00022087 2016-07-19
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00512993 2015-03-05
NATAN
GBG Forschungs GmbH
Phase 3 Completed
NCT00320710 2014-08-22
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Novartis
Phase 3 Completed
NCT00712985 2014-04-24
CTIBL
Milton S. Hershey Medical Center
Phase 3 Completed
NCT00049452 2014-01-06
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00301886 2013-11-13
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
Phase 3 Withdrawn
NCT00072020 2013-08-02
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00326820 2013-03-13
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Wales Cancer Trials Unit
Phase 3 Unknown
NCT00171340 2012-04-16
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Novartis
Phase 3 Completed
NCT00171314 2012-04-11
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Novartis
Phase 3 Completed
NCT00375427 2012-04-11
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Novartis
Phase 3 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed
NCT00376740 2011-08-23
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
Soroka University Medical Center
Phase 3 Completed
NCT00372710 2009-11-23
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Novartis
Phase 3 Terminated